Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (September 2020)
34 slides from Genprex's investor presentation, Sep 29, 2020
Slide 1: Reprogramming the Course of Cancer and Diabetes
©) Genprex REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are “forward-lookingstatements” within the meaning ofthe Private Securities Litigation Reform Actof 1995. Because such statements are subjectto risks and uncertainties, actual results
Slide 3: GNPX at a Glance
GNPX AT A GLANCE DATA AS OF SEPTEMBER 25, 2020 Genprex,Inc. _-GNPX Nasdaq 9237 130M aK Cash as of June 30, 2020: $22,127,179 Oustonding shores areas of gust 7, 2020. Genprex Nasdaq: GNPX
Slide 4: Major Competitive Advantages
MAJOR COMPETITIVE ADVANTAGES WE HAVE A GENE THERAPY PLATFORM. Ournon-viral nanoparticle delivery system is designed to deliver a variety of therapeutic genesto fight cancer. Data indicate ‘hatour lead drug candidate, GPX-001, may be combined with a numberof approved cancer drugs, and that itmay be e
Slide 5: Executive Summary
EXECUTIVE SUMMARY MAJOR COMPETITIVE ADVANTAGES DEMONSTRATED CLINICAL ACHIEVEMENT + GENE THERAPY PLATFORM INITIATING TWO LUNG CANCER TRIALS + LARGE MARKETS AND UNMET NEED IN 2021 WORLD-CLASS ACADEMIC PARTNERS + COMBINATION TRIALS WITH TOP SELLING CANCER DRUGS EXPANDING PIPELINE + FDA FAST TRACK DESIG
Slide 6: Fast Track Designation
FAST TRACK DESIGNATION * i eM Genprex received Fast Track Designation for GPX-001 + EGFR inhibitor osimertinib (AstraZeneca's Tagrisso®) for NSCLC patients that progressed on ‘osimertinib alone. Tagrisso® had $3B+ worldwide gross sales in 2019, and itis AZ’s highest grossing product. FTD is for ther
Slide 7: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE PATHWAY TO APPROVAL PRECUNICAL cunicat CUNCAL CCUNICAL PHASE PHASE2 PHASES : DIABETES: Hi us roarerecoeein © Genprex Nasdaq: GNX
Slide 8: GPX-001 + Tagrisso: General Study Characteristics
GPX-001 + TAGRISSO® GENERAL STUDY CHARACTERISTICS + GPX-001 in combination with AstraZeneca’s Tagrisso (osimertinib) for NSCLC + FDA Fast Track Designation + Patients with Stage 4, EGFR mutant NSCLC whose disease progressed after Tagrisso + “10 US. sites + 100 patients Phaze I: 9-18 patients Phase I
Slide 9: GPX-001 + Tagrisso: Endpoints
GPX-001 + TAGRISSO® pi ad + 343 dose escalation of GPX-001 PRIMARY ENDPOINT ae in combination with Tagrisso + Dose limiting toxicity ie) ice ae eo. ts) PRIMARY ENDPOINT SECONDARY ENDPOINTS + Randomized 1:1, open-label, 2-arm study of GPX-001 in combination with Tagrisso vs. Tagrisso monotherapy + Pr
Slide 10: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES © Genprex’s oncology combination treatment approach utilizes targeted therapies and immunotherapies. © Planned clinical trials include combinations with osimertinib (AstraZeneca’s top selling drug Tagr
Slide 11: Oncology Program
Slide 12: Non-Small Cell Lung Cancer
NON-SMALL CELL LUNG CANCER MARKET STATISTICS A% 3B+ MOST COMMON LUNG CANCER TAGRISSO® 2019 SALES. NSCLC represents the majority of all lung cancers. AstraZeneca’s highest grossing product. 11B+ WORLDWIDE CASES KEYTRUDA® 2019 SALES. ‘Almost two million cases per year worldwide. Merck's highest grossi
Slide 13: Problem: Few Patients Benefit from Modern Therapies
PROBLEM: FEW PATIENTS BENEFIT FROM MODERN THERAPIES LIMITATIONS TO NSCLC TREATMENT TARGETED THERAPIES IMMUNOTHERAPIES. PATIENT ELIGIBILITY Of patients havean activating Of patients are eligible for EGFR mutation and can benefit ‘and benefit from from targetedtherapies! Immunetherapies? “Few patients
Slide 14: Solution: Novel Platform to Treat Cancer
SOLUTION: NOVEL PLATFORM TO TREAT CANCER ONCOPREX™ NANOPARTICLE DELIVERY PLATFORM GENES Multiple tumor suppressor genes SYNERGIES Modern approach using combination therapy CANCERS Genetic mutations found in other cancers Genprex asaag:NPX
Slide 15: Oncoprex Nanoparticle Delivery Platform
ONCOPREX™ NANOPARTICLE DELIVERY PLATFORM CATIONIC LIPID NANOVESICLE CARRIES DRUG TO TUMORS Positively charged ‘nanovesicle TOS oo Cassette So ° ° Negatively charged cancer cell Nanovesicle attaches to Cancer‘killing genes Cell death cancer cell like a magnet integrate into cell Our non-viral, biodeg
Slide 16: GPX-001 Targets Cancer at Its Core
GPX-001 TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 2 y\ aN 9000 @ CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS = MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer ‘Nasdaq: GNPX
Slide 17: GPX-001 Inhibits Key Cell Signaling
GPX-001 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS Cell Survival Proliferation ‘Nasdaq: GNPX
Slide 18: GPX-001 Affects Tumor Immunogenicity
GPX-001 AFFECTS TUMOR IMMUNOGENICITY TUSC2 ALSO SHOWN TO UPREGULATE NK AND CD8+ T CELLS, AND DOWNREGULATE PD-L1 RECEPTORS IL15 | ube (ee 20. J \ toe ve 2 Ribosome IL-5 ? ILas Immature Mature NK cells NK cells ‘Nasdaq: GNPX
Slide 19: Dose Escalation Study
DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase | monotherapy results: GPX-001 MONOTHERAPY ONC-001 TRIAL 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Maximum Tolerated
Slide 20: GPX-001 + Erlotinib Combination
GPX-001 + ERLOTINIB COMBINATION PHASE Il PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS LINE OF -ATIENT EGFR STATU JOR THERAPY iu EGER THERAPY Positive (exon 18420) aR Chemo, 3 Negative 24% regression Target Lesion Chemo /anti-PD1 2 30% regression one Target Lesion é Negative 1836 regre
Slide 21: GPX-001 + Erlotinib Combination: Swimmer Plot
EGFR status/mutation GPX-001 + ERLOTINIB COMBINATION Swimmer Plot of Best Response, with Time on Study Negative 4 Negative + Positive (exon 18+20) + Negative 4 Negative + Negative 4 Negative + Negative + Positive (exon 21) 4 Negative + Negative 4 Positive (exon 21) + sD + Chemotherapy ‘4 Chemotherap
Slide 22: GPX-001 Shows Synergy with Immunotherapies
GPX-001 SHOWS SYNERGY WITH IMMUNOTHERAPIES TUSC2 IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER Survival on Lung Metastasis Model ites Siaiad ‘igiSaiesa TUSC2+PDIeCTLA tEEEE 10 78 20 3 Days TUSC2+anti-PD1 combination significantly prolonged survival in a lung metastasis model
Slide 23: GPX-001 Shows Synergy with Immunotherapies
GPX-001 SHOWS SYNERGY WITH IMMUNOTHERAPIES TUSC2 IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER TUSC2 + PEMBRO Strong antitumor immune responses of anti-PD1 were found against PDX tumors developed in humanized mice. TUSC2 + PEMBRO + CHEMO. TUSC2+anti-PD1+chemo combination res
Slide 24: Diabetes Program
n= Ee i oVU <2 Oa
Slide 25: Diabetic Patients in Need of Modern Therapy
DIABETIC PATIENTS IN NEED OF MODERN THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S, or 10 percent of the U.S. population. May replace daily burden of blood glucose monitoring and insulin replacement the
Slide 26: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an ro, AAV vector to deliver the Pdx1 and MafAgenes to Hypersemia ay the pancreas. Intaduetatinfson ae ad Transforms alpha cells in the pancreas into fascia functional beta-lke ce
Slide 27: Key Milestones Through Early 2021
KEY MILESTONES THROUGH EARLY 2021 CLINICAL Continue preparations for combination clinical trials of GPX-001 with Tagrisso® + Complete preparation of lipid nanoparticle delivery system and TUSC2 DNA plasmid for clinical expansion + Complete manufacturing scale-up to support trial site expansion and c
Slide 28: Some Targeted Therapy Company Valuations
SOME TARGETED THERAPY COMPANY VALUATIONS PHASE VALUATION ‘COMP? 0 DRUG | own | swear | comce | nooo” lew EtaRse Melanoma, Head and Neck, rumor infitrating tovance lova wasdog “cone NSCLC chron plocherspeis LymphocyticLeukemia Mic! Theapeuts MTA nasdaq NSCLE Colorect Renal yrs, stravatnb ax Entinosta
Slide 29: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman & Chief Executive Officer 30+ years of expertisein corporate law, including corporate governance, in biotech industry + Former owner of securities broker dealer firm MICHAEL REDMAN Executive VP & Chief Operating Officer + 30+ years of exper
Slide 30: Meet Our Team
ss MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD Senior Vice President, IP and Licensing 20+ years of expertise in biotech |P law, business ‘developmen, licensing transactions + Seasoned|P executive and axorney SHANNON INMAN Vice President of Global Clinical Operations + 20+ years of clinica
Slide 31: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD PASI ANTERO JANNE MD, PhD JACK A. ROTH = MD. FACS, Chairman \e MM Professor and Bud Johnson Distinguished Clinical Chair, Department of Thoracicand Cardiovascular Surgery; Chief, Section of Thoracic Molecular Oncology: Professor af Molecular and Cellular Oncol
Slide 32: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board + 30+ years of expertise in corporate law, including ‘corporate governance, in biotech industry + Former owner of securities broker dealer firm JOSE A. MORENO TOSCANO Board Director + Chief Executive Officer, LFB USAInc + 20+yy
Slide 33: We Believe in a Future of Transformational Patient Care
WE BELIEVE IN A FUTURE OF TRANSFORMATIONAL PATIENT CARE 21ST CENTURY GENE THERAPIES MARKET GAPS AND UNMET NEED COMBINATION TRIALS WITH TOP SELLING DRUGS SCALING UP MANUFACTURING EXPLORING NEW INDICATIONS AND PARTNERSHIPS ‘Nasdaq: GNPX
Slide 34: Genprex Contact
QO Genprex’ NASDAQ: GNPX, 1601 Trinity St, Bldg B, #3.312.09, Austin, Texas 78712 (877)774-GNPX | investors@genprex.com ‘Nasdaq: GNPX